Additionally, elevated IL-8 levels have been correlated with resistance to EGFR inhibitors and poorer patient outcomes of lung cancer, highlighting its potential as both a therapeutic target and a prognostic biomarker [19]. This evidence concerns the gene CXCL8 and lung cancer.